Implementing Evidence-Based Tobacco Treatment Interventions in Oncology to Achieve Optimal Outcomes
Menée aux Etats-Unis à partir de données d'enquêtes réalisées en 2021 auprès de 692 662 patients atteints d'un cancer, cette étude multicentrique analyse les facteurs de réussite du sevrage tabagique des patients fumeurs après la mise en oeuvre
Among the thousands of individuals diagnosed with cancer each year, a substantial minority of individuals smoke or use other tobacco products at the time of diagnosis,1 with particularly high rates among individuals diagnosed with lung or head/neck cancer.2 It is without doubt that quitting tobacco use after a cancer diagnosis is associated with improved outcomes across many domains, including mortality, morbidity, and quality of life.3 However, individuals who smoke or use tobacco at the time of diagnosis face significant challenges in achieving cessation, including stigma and biases stimulated by decades of effective but aggressive public health and tobacco control messages.4 A group of clinicians and researchers led by National Cancer Institute (NCI)5 has recently published a monograph comprehensively addressing the importance of integrating evidence-based tobacco treatment and smoking cessation into the cancer care setting.6 Unfortunately, data have consistently documented limited implementation of tobacco treatment in oncology,7 whether it be at NCI-designated cancer centers,8 among the broader cancer care community,9 or among more targeted malignances that are more likely to be linked to smoking and tobacco use as a potential cause.